Perspectives From Patients and Gastroenterologists on De-escalating Therapy for Crohn's Disease.

Authors :: Siegel CA
Thompson KD
Walls D
Gollins J
Buisson A
Olympie A
Beaugerie L
Colombel JF
Louis E
Source :: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2021 Feb; Vol. 19 (2), pp. 403-405. Date of Electronic Publication: 2019 Dec 27.
Publication Year :: 2021
Abstract: In Crohn's disease, combination therapy with anti-tumor necrosis factor (anti-TNF) agents and azathioprine/mercaptopurine has been shown to be superior to monotherapy with one of these treatments alone. <superscript>1</superscript> This combination has its best success rate when used early in the course of treatment. <superscript>2</superscript> However, because of the significant cost of these drugs and concerns over long-term side effects, <superscript>3</superscript> <superscript>,</superscript> <superscript>4</superscript> many patients and providers often ask about stopping one or both of these medications.<br /> (Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.)

Subjects :: Azathioprine adverse effects
Humans
Immunosuppressive Agents adverse effects
Infliximab adverse effects
Mercaptopurine
Tumor Necrosis Factor Inhibitors
Crohn Disease drug therapy
Gastroenterologists

Language :: English
ISSN :: 1542-7714
Volume :: 19
Issue :: 2
Database :: MEDLINE
Journal :: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Publication Type :: Academic Journal
Accession number :: 31887442
Full Text :: https://doi.org/10.1016/j.cgh.2019.11.062

Full Text Access

Tools